Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
MJFF Publications
Donate
Access Resources

MJFF Publications

The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.

 From
To
  • Default content image

    The Michael J. Fox Foundation’s development and distribution of novel alpha-synuclein viral vectors to study Parkinson's disease.

    The Michael J. Fox Foundation’s development and distribution of novel alpha-synuclein viral vectors to study Parkinson's disease.  Elisia M. Clark*, Nicole K. Polinski*, Bradford Casey*, Tomas…
    Learn more
  • Default content image

    LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

    Learn more
  • Default content image

    The Michael J. Fox Foundation’s Efforts to Develop New Tools for Understanding LRRK2 Biology and the Role of LRRK2 in Parkinson’s Disease Pathology

    As the greatest known genetic contributor to Parkinson's disease (PD), the leucine-rich repeat kinase 2 (LRRK2) gene and protein are targets of interest for Parkinson’s disease research and…
    Learn more
  • Default content image

    The Michael J. Fox Foundation’s Efforts to Understand the Relationship between GBA1 and Alpha-Synuclein through the Development and Characterization of Preclinical Models

    Heterozygous mutations in the GBA1 gene--which encodes for lysosomal glucocerebrosidase (GCase)--are the most common genetic risk factor for Parkinson’s disease (PD). In addition, decreased GCase…
    Learn more
  • Default content image

    Characterization of a humanized A53T alpha-synuclein (aSyn A53T KI) and alpha-synuclein KO (aSyn KO) models

    Mutations and multiplications in the SNCA gene encoding the alpha-synuclein protein are linked to an autosomal dominant form of Parkinson’s disease (PD). One such mutation is the alanine-to-threonine…
    Learn more
  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Antibody Tools for Investigating Rab Molecular Biology

    A field-wide challenge in Parkinson’s disease (PD) research is a general lack of availability for high-quality, reproducible, and readily accessible preclinical research tools. To address these…
    Learn more
  • Default content image

    Cell Line Resources from Parkinson’s Progression Markers Initiative (PPMI) Participants

    The Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal observational study conducted at over thirty international sites that collects data and biospecimens from idiopathic Parkinson…
    Learn more

Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.

 From
To
  • Default content image

    Alpha-Synuclein: A Therapeutic Target and Potential Biomarker in Parkinson's Disease

    A detailed discussion of our current understanding of alpha-synuclein biology and the ongoing research and development surrounding its role in Parkinson's disease.
    Learn more
  • Default content image

    Diagnosis and Management of Neurodegenerative Atypical Parkinsonism

    A detailed consideration of the neurodegenerative diseases that can cause parkinsonism including dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP)…
    Learn more
  • Default content image

    Deep Brain Stimulation and Magnetic Resonance-guided Focused Ultrasound

    A review of innovations in surgical Parkinson's disease treatments, inlcuding deep brain stimulation and magnetic resonance-guided focused ultrasound.
    Learn more
  • Default content image

    Dystonia and Parkinson's Disease

    An exploration of the various manifestations of dystonia in the context of Parkinson's disease.
    Learn more
  • Default content image

    Levodopa 2.0: New Strategies to Even Out the Peaks and Valleys

    A discussion on the latest in new formulations and supplemental therapies of levodopa.
    Learn more
  • Default content image

    Dementia with Lewy Bodies: In the News and in the Clinic

    A practical review of the diagnosis and management of dementia with Lewy bodies.
    Learn more

Michael J. Fox Foundation publications supported through our OAP program.

We believe that the results of all MJFF-funded research should be promptly published and broadly disseminated to accelerate innovation and foster collaboration toward our shared goal of new treatments and cures for Parkinson’s disease. 

Request open access coverage funds for your MJFF project here

 From
To
  • Default content image

    Evaluation of the PREDIGT Score’s Performance in Identifying Newly Diagnosed Parkinson’s Patients Without Motor Examination

    Several recent publications described algorithms to identify subjects with Parkinson’s disease (PD). In creating the “PREDIGT Score”, we previously developed a hypothesis-driven, simple-to-use…
    Learn more
  • Default content image

    LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease

    Leucine-rich repeat kinase 2 (LRRK2) is a kinase involved in different cellular functions, including autophagy, endolysosomal pathways, and immune function. Mutations in LRRK2 cause autosomal…
    Learn more
  • Default content image

    Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms

    Background: The development of therapeutics for Parkinson's disease (PD) requires the establishment of biomarker assays to enable stratifying patients, monitoring disease progression, and assessing…
    Learn more
  • Default content image

    Cortical and Subthalamic Nucleus Spectral Changes During Limb Movements in Parkinson's Disease Patients with and Without Dystonia

    Background: Dystonia is an understudied motor feature of Parkinson's disease (PD). Although considerable efforts have focused on brain oscillations related to the cardinal symptoms of PD, whether…
    Learn more
  • Default content image

    Lipase regulation of cellular fatty acid homeostasis as a Parkinson's disease therapeutic strategy

    Synucleinopathy (Parkinson's disease (PD); Lewy body dementia) disease-modifying treatments represent a huge unmet medical need. Although the PD-causing protein α-synuclein (αS) interacts with lipids…
    Learn more
  • Default content image

    Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts

    Despite several advances in the field, pharmacodynamic outcome measures reflective of LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and approaches have been…
    Learn more
  • Default content image

    Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson's Disease Trials

    Background: The Parkinson's Disease Patient Report of Problems (PD-PROP) captures the problems and functional impact that patients report verbatim. Online research participation and advances in…
    Learn more
Female researcher pipetting in lab.

Breaking Research Updates

Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.

Read Research News
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.
Here. Until Parkinson's isn't.
Join us as we work to find a cure for the 6 million people worldwide living with Parkinson's.
 
 
 
 
Month
Day
Year